Quantum annealer-based molecular docking methods can be integrated with experimental evolution data to predict how antibiotic resistance mutations alter protein-ligand binding geometries.
Adversarial Debate Score
60% survival rate under critique
Model Critiques
Supporting Research Papers
- A Physically-Informed Subgraph Isomorphism Approach to Molecular Docking Using Quantum Annealers
Molecular docking is a crucial step in the development of new drugs as it guides the positioning of a small molecule (ligand) within the pocket of a target protein. In the literature, a feasibility st...
- Exploiting evolutionary trade-offs to combat antibiotic resistance
Antibiotic resistance frequently evolves through fitness trade-offs in which the genetic alterations that confer resistance to a drug can also cause growth defects in resistant cells. Here, through ex...
- Conditionally Site-Independent Neural Evolution of Antibody Sequences
Common deep learning approaches for antibody engineering focus on modeling the marginal distribution of sequences. By treating sequences as independent samples, however, these methods overlook affinit...
- Binding Free Energies without Alchemy
Absolute Binding Free Energy (ABFE) methods are among the most accurate computational techniques for predicting protein-ligand binding affinities, but their utility is limited by the need for many sim...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Quantum annealer-based molecular docking (QA-MD) algorithms, when trained or calibrated using experimental evolution datasets containing characterized antibiotic resistance mutations, will predict protein-ligand binding geometries (RMSD, binding pose, key contact residues) for mutant proteins with statistically superior accuracy compared to classical docking methods (AutoDock Vina, Glide SP) for at least 3 distinct antibiotic-target systems, achieving mean RMSD ≤ 2.0 Å versus crystallographic or cryo-EM ground truth structures, with a minimum 15% improvement in binding pose prediction accuracy over classical baselines.
- QA-MD predictions achieve mean RMSD > 2.5 Å across all tested systems compared to experimental structures, with no statistically significant improvement over AutoDock Vina baseline (p > 0.05, paired t-test).
- Binding pose prediction accuracy (fraction of poses within 2.0 Å RMSD) is ≤ classical methods in ≥2 of 3 test systems.
- Integration of experimental evolution data provides no measurable improvement (ΔAccuracy < 5%) over QA-MD without evolution data.
- Predicted resistance-conferring mutations show ≤ 0.5 correlation (Pearson r) with experimentally measured MIC fold-changes.
- Quantum annealing solution quality (as measured by energy gap from known optimal) degrades to classical simulated annealing levels when problem size exceeds 200 residues.
- Computational wall-clock time exceeds 10× classical methods without proportional accuracy gain.
Experimental Protocol
Minimum Viable Test (MVT): Focus on three well-characterized antibiotic-resistance systems: (1) E. coli DHFR + trimethoprim (TMP), (2) S. aureus PBP2a + beta-lactams, (3) M. tuberculosis InhA + isoniazid. Use existing DMS (deep mutational scanning) datasets for each. Encode docking problem as QUBO on D-Wave Advantage. Compare predicted binding geometries against PDB crystal structures of mutant-drug complexes. Primary metric: RMSD of predicted vs. experimental binding pose. Secondary metric: Pearson correlation of predicted ΔΔG with experimental MIC fold-change. Run 3 independent replicates per system. Statistical test: Wilcoxon signed-rank test vs. AutoDock Vina baseline, α = 0.05.
- PDB structures: Wild-type and mutant complexes for DHFR (PDB: 1RX2, 1RX4, 3FRE), PBP2a (PDB: 1VQQ, 4CJN), InhA (PDB: 2X22, 2NSD) — publicly available.
- DMS/experimental evolution datasets: Stiffler et al. 2015 (DHFR, n=259 variants), Deng et al. 2017 (PBP2a, n=~200), Bershtein et al. 2012 (InhA, n=~150) — publicly available.
- MIC datasets: PATRIC database (https://www.patricbrc.org), EUCAST breakpoint tables — publicly available.
- D-Wave Leap cloud access: Minimum 20 hours QPU time on Advantage system — requires subscription (~$2,000/month academic).
- Classical baseline software: AutoDock Vina 1.2, Glide SP (Schrödinger Suite academic license ~$5,000/year).
- Molecular dynamics validation: GROMACS 2023 with AMBER ff19SB force field — open source.
- QUBO encoding library: Ocean SDK (D-Wave, open source) + custom protein-ligand encoding scripts.
- Protein preparation: Schrödinger Protein Preparation Wizard or OpenBabel + PDB2PQR — partially open source.
- Primary: Mean RMSD of QA-MD predictions ≤ 2.0 Å vs. experimental structures across all 3 systems (individual system threshold: ≤ 2.5 Å).
- Comparative: QA-MD achieves ≥15% lower mean RMSD than AutoDock Vina (p < 0.0083 after Bonferroni correction).
- Evolution integration: Including experimental evolution data improves RMSD by ≥5% and ΔΔG correlation by ≥0.1 Pearson r units vs. QA-MD alone.
- Resistance prediction: Pearson r ≥ 0.6 between predicted ΔΔG and log2(MIC fold-change) across all mutants.
- Reproducibility: CV (coefficient of variation) of RMSD across 3 replicates ≤ 15%.
- Computational: QA-MD achieves target accuracy within 2× wall-clock time of classical methods (acceptable trade-off threshold).
- Mean RMSD > 2.5 Å in ≥2 of 3 systems.
- No statistically significant improvement over AutoDock Vina (p > 0.0083) in any system.
- Evolution data integration provides ΔRMSD < 2% (noise-level improvement).
- Pearson r < 0.4 for ΔΔG vs. MIC correlation.
- Chain break fraction > 10% in >50% of QA submissions (hardware quality failure).
- QA-MD runtime > 50× classical methods without accuracy justification.
- Homology models for >30% of mutants fail quality thresholds, reducing dataset below statistical power threshold (n < 35 per system).
480
GPU hours
70d
Time to result
$8,500
Min cost
$47,000
Full cost
ROI Projection
- SaaS platform potential: Quantum resistance prediction as a service for pharma companies; comparable platforms (Schrödinger, Atomwise) valued at $1–3B. Addressable market: ~$800M/year in computational drug discovery services.
- Licensing: QA-MD-evolution integration IP licensable to D-Wave, IBM, IonQ as validated use case — estimated $5–20M licensing value.
- Diagnostic applications: Rapid resistance genotype-to-phenotype prediction for clinical microbiology labs; market size ~$4B/year globally.
- Agricultural antibiotics: Veterinary antibiotic resistance prediction (same methodology); market ~$1.2B/year.
- Government contracts: NIH NIAID, BARDA, DARPA all fund antibiotic resistance tools; realistic grant portfolio $5–15M over 5 years if validated.
- Partnership value: Validated methodology positions for partnership with major pharma (AstraZeneca, Pfizer have active AMR programs) — potential $50–200M collaboration agreements.
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1QA-MD-clinical-resistance-prediction-005
- 2quantum-drug-design-optimization-006
- 3evolution-informed-virtual-screening-007
- 4QA-MD-ESKAPE-pathogens-008
- 5quantum-polypharmacology-009
Prerequisites
These must be validated before this hypothesis can be confirmed:
- QA-QUBO-protein-encoding-validation-001
- DMS-dataset-standardization-002
- AlphaFold2-mutant-structure-accuracy-003
- AMBER-GAFF2-small-molecule-parameterization-004
Implementation Sketch
# Quantum Annealer Molecular Docking + Evolution Integration Pipeline # Architecture: Hybrid Classical-Quantum Pipeline ## MODULE 1: Data Preparation class ProteinLigandSystem: def __init__(self, pdb_id, mutation_list, dms_dataset): self.structure = load_pdb(pdb_id) # BioPython self.mutations = mutation_list # [(pos, WT_aa, mut_aa), ...] self.dms_data = dms_dataset # {mutation: MIC_fold_change} def prepare_structure(self, mutation): # Apply point mutation using PyRosetta pose = rosetta.pose_from_pdb(self.structure) mutant_pose = apply_point_mutation(pose, mutation) minimize_energy(mutant_pose, scorefxn='ref2015') return mutant_pose def get_evolution_prior(self, mutation): # Convert MIC fold-change to energy prior mic_fc = self.dms_data.get(mutation, 1.0) # Higher MIC = weaker binding = positive energy penalty return 0.5 * np.log2(mic_fc) # kcal/mol units ## MODULE 2: QUBO Formulation class DockingQUBO: def __init__(self, protein_pose, ligand_mol, grid_spacing=0.5, angle_step=15): self.protein = protein_pose self.ligand = ligand_mol self.grid = generate_binding_site_grid(protein_pose, spacing=grid_spacing) self.angle_bins = np.arange(0, 360, angle_step) def encode_ligand_pose(self): # Binary encoding: one-hot for translation + torsion angles n_grid = len(self.grid) # ~1000 grid points n_torsions = self.ligand.n_rotatable_bonds n_angles = len(self.angle_bins) # 24 bins # Total qubits: n_grid * 3 (xyz) + n_torsions * n_angles # For typical ligand: ~3000 + 15*24 = ~3360 qubits self.n_qubits = n_grid + n_torsions * n_angles return self.n_qubits def compute_energy_matrix(self, evolution_prior=0.0): # Q matrix for QUBO: Q[i,j] = interaction energy Q = np.zeros((self.n_qubits, self.n_qubits)) # Diagonal: single-variable energies (LJ + electrostatics) for i, pose_var in enumerate(self.pose_variables): Q[i,i] = self.compute_vdw_energy(pose_var) + \ self.compute_electrostatic_energy(pose_var) + \ evolution_prior # Evolution data integration # Off-diagonal: pairwise constraints (one-hot enforcement) for group in self.one_hot_groups: for i, j in combinations(group, 2): Q[i,j] += 10.0 # Penalty for selecting >1 in group return Q def add_evolution_constraint(self, evolution_prior): # Modify Q matrix based on experimental evolution data # Mutations with high MIC get increased binding energy penalties binding_site_residues = self.get_binding_site_residues(cutoff=4.0) for residue_idx in binding_site_residues: qubit_indices = self.residue_to_qubit_map[residue_idx] for qi in qubit_indices: self.Q[qi, qi] += evolution_prior * self.contact_weight[residue_idx] return self.Q ## MODULE 3: Quantum Annealing Execution class QuantumDockingSolver: def __init__(self, sampler='hybrid'): if sampler == 'hybrid': from dwave.system import LeapHybridCQMSampler self.sampler = LeapHybridCQMSampler() else: from dwave.system import DWaveSampler, EmbeddingComposite self.sampler = EmbeddingComposite(DWaveSampler()) def solve(self, Q_matrix, n_reads=1000, annealing_time=100): bqm = dimod.BinaryQuadraticModel.from_qubo(Q_matrix) if self.sampler_type == 'hybrid': response = self.sampler.sample(bqm, time_limit=60) else: response = self.sampler.sample(bqm, num_reads=n_reads, annealing_time=annealing_time, chain_strength=self.auto_chain_strength(Q_matrix)) # Extract best solution best_sample = response.first.sample chain_break_fraction = response.first.chain_break_fraction assert chain_break_fraction < 0.05, f"Chain breaks too high: {chain_break_fraction}" return self.decode_pose(best_sample), response.first.energy def decode_pose(self, binary_sample): # Convert binary solution back to 3D coordinates translation = self.decode_translation(binary_sample) rotations = self.decode_rotations(binary_sample) torsions = self.decode_torsions(binary_sample) return LigandPose(translation, rotations, torsions) ## MODULE 4: Validation and Comparison class ValidationPipeline: def compute_rmsd(self, predicted_pose, experimental_pose): # Heavy-atom RMSD after optimal superposition return rdMolAlign.CalcRMS(predicted_pose.mol, experimental_pose.mol) def run_classical_baseline(self, protein_pdbqt, ligand_pdbqt): # AutoDock Vina result = subprocess.run(['vina', '--receptor', protein_pdbqt, '--ligand', ligand_pdbqt, '--exhaustiveness', '32', '--num_modes', '10'], capture_output=True) return parse_vina_output(result.stdout) def statistical_comparison(self, qa_rmsds, classical_rmsds): stat, p_value = scipy.stats.wilcoxon(qa_rmsds, classical_rmsds) effect_size = cohens_d(qa_rmsds, classical_rmsds) return {'p_value': p_value, 'effect_size': effect_size, 'qa_mean': np.mean(qa_rmsds), 'classical_mean': np.mean(classical_rmsds)} ## MODULE 5: Main Pipeline def run_evp(systems, n_mutants_per_system=50): results = {} for system in systems: # ['DHFR', 'PBP2a', 'InhA'] pls = ProteinLigandSystem(system.pdb_id, system.mutations, system.dms_data) qa_rmsds, classical_rmsds = [], [] for mutation in system.mutations[:n_mutants_per_system]: # Prepare mutant structure mutant_pose = pls.prepare_structure(mutation) evolution_prior = pls.get_evolution_prior(mutation) # QA docking with evolution integration qubo = DockingQUBO(mutant_pose, system.ligand) Q = qubo.compute_energy_matrix(evolution_prior) solver = QuantumDockingSolver(sampler='hybrid') qa_pose, qa_energy = solver.solve(Q) # Classical baseline validator = ValidationPipeline() classical_pose = validator.run_classical_baseline(mutant_pose, system.ligand) # Compute RMSD vs experimental exp_pose = load_experimental_pose(system, mutation) qa_rmsds.append(validator.compute_rmsd(qa_pose, exp_pose)) classical_rmsds.append(validator.compute_rmsd(classical_pose, exp_pose)) results[system.name] = validator.statistical_comparison(qa_rmsds, classical_rmsds) # Abort checkpoint if results[system.name]['p_value'] > 0.1 and system.name == 'DHFR': print("ABORT: First system shows no signal. Reassess QUBO formulation.") break return results
CHECKPOINT 1 (Day 14): Homology model quality check. ABORT if >40% of mutant models fail MolProbity threshold (score >2.5). Action: Expand to RosettaRelax refinement or restrict to experimentally resolved structures only.
CHECKPOINT 2 (Day 25): QUBO encoding validation on toy system. ABORT if alanine dipeptide conformational sampling RMSD >1.0 Å vs. MD reference. Action: Revisit discretization scheme (reduce angle step to 10°) or energy function parameterization.
CHECKPOINT 3 (Day 32): First QA submission quality check (DHFR system, 10 mutants). ABORT if chain break fraction >15% in >50% of submissions OR if QA energy is higher than classical simulated annealing in >80% of cases. Action: Recheck embedding, reduce problem size, or switch to hybrid solver.
CHECKPOINT 4 (Day 40): Interim RMSD comparison (DHFR system complete). ABORT if QA-MD mean RMSD >3.5 Å AND shows no improvement trend over classical (p > 0.2). Action: Reassess QUBO energy function; consider switching to variational quantum eigensolver (VQE) approach.
CHECKPOINT 5 (Day 55): MD validation stability check. ABORT if >50% of QA-MD poses show RMSD drift >3.0 Å during 100 ns MD (indicating physically unrealistic starting poses). Action: Apply more stringent steric clash filtering; increase QA reads to 5,000.
CHECKPOINT 6 (Day 62): Ablation study result. ABORT full publication pathway (but not analysis) if evolution data integration provides <2% RMSD improvement — reframe as negative result demonstrating QA-MD standalone performance.